The Pediatric Neuroblastoma Treatment by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).
Learn More On The Pediatric Neuroblastoma Treatment Market:
According to The Business Research Company’s Pediatric Neuroblastoma Treatment, The pediatric neuroblastoma treatment market size has grown rapidly in recent years. It will grow from $1.67 billion in 2023 to $1.84 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to advancements in treatment modalities, increased awareness and early diagnosis, research and development initiatives, collaborative efforts, improved survival rates.
The pediatric neuroblastoma treatment market size is expected to see strong growth in the next few years. It will grow to $2.58 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to emerging therapies, personalized medicine, global health initiatives, expanded access to treatment, patient advocacy and support. Major trends in the forecast period include collaborative research initiatives, gene therapy breakthroughs, novel drug development, early diagnosis and screening, patient advocacy and support.
The rising number of new cases of pediatric neuroblastoma is expected to propel the growth of the pediatric neuroblastoma treatment market going forward. The rising prevalence of neuroblastoma is increasing the demand for pediatric neuroblastoma treatment alternatives. As a result, pharmaceutical corporations and other stakeholders have boosted their investment in research and development, promoting innovation in the industry. Furthermore, the availability of new diagnostic technology and screening procedures has resulted in earlier neuroblastoma discovery, allowing for earlier treatments and better outcomes. For instance, in March 2023, according to an article published by the American Society of Clinical Oncology (ASCO), a US-based organization for oncology professionals and physicians, neuroblastoma affects approximately 700 to 800 youngsters in the United States each year. In the United States, neuroblastoma accounts for 6% of all childhood malignancies. Neuroblastoma affects around 90% of children under the age of five. Therefore, the rising number of new cases of pediatric neuroblastoma is driving the growth of the pediatric neuroblastoma treatment market.
Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=9924&type=smp
The pediatric neuroblastoma treatment market covered in this report is segmented –
1) By Treatment Type: Immunotherapy, Chemotherapy, Radiation Therapy, Other Treatment Types
2) By Risk Group: Low Risk, Intermediate Risk, High Risk
3) By End User: Hospitals, Specialty Clinics, Other End Users
Top Major Players:
- United Therapeutics Corporation
- APEIRON Biologics AG
- Baxter International Inc.
- Cell Ectar Biosciences Inc.
- Pfizer Inc.
North America was the largest region in the pediatric neuroblastoma treatment market in 2023.
Research and development are the key trend gaining popularity in the pediatric neuroblastoma treatment market. Major companies operating in the pediatric neuroblastoma treatment market are focusing on advance research and development to sustain their position in the market. For instance, in March 2021, Ascentage Pharma Group Inc., a US-based pharmaceutical company that develops novel cancer therapies, announced that the US Food and Drug Administration (FDA) had designated alrizomadlin (APG-115) as a rare pediatric disease (RPD) for the treatment of neuroblastoma. The FDASIA, which went into force in 2012, introduced the rare pediatric disease priority review voucher (PRV) program to reward sponsors for the discovery of innovative medicines for the treatment of rare pediatric disorders. Ascentage Pharma is developing alrizomadlin, an orally given, selective, small-molecule antagonist of the MDM2 protein. Alrizomadlin has a high affinity for MDM2 and is intended to stimulate p53's tumor suppressive activities by inhibiting the MDM2-p53 protein-protein connection.
The pediatric neuroblastoma treatment market report table of contents includes:
1. Executive Summary
2. Pediatric Neuroblastoma Treatment Market Characteristics
3. Global Pediatric Neuroblastoma Treatment Market Trends And Strategies
4. Pediatric Neuroblastoma Treatment Market - Macro Economic Scenario
5. Global Pediatric Neuroblastoma Treatment Market Size and Growth
…….
26. Global Pediatric Neuroblastoma Treatment Market Competitive Benchmarking
27. Global Pediatric Neuroblastoma Treatment Market Competitive Dashboard
28. Key Mergers and Acquisitions Pediatric Neuroblastoma Treatment Market
29. Pediatric Neuroblastoma Treatment Market Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
The global Immunotherapy market is all set to gain substantial demand opportunities from various end-use industries, according to a new report from Factor.
Detailed information on consumptions and demand ratio of diverse products/services linked to the growth dynamics of the Pediatric Neuroblastoma Treatment market is covered in this report.
This aside, the report presents reliable data on revenues and volumes of all key geographical regions during the forecast period 2020 to 2026.The report on the global Pediatric Neuroblastoma Treatment market works as a helpful guide that provides dependable data on various aspects such as challenges and opportunities in this market.
In addition to this, readers of this report will get an in-depth analysis of diverse trends together with technological and product developments in the global Pediatric Neuroblastoma Treatment market.
The analysts have used diverse business intelligence tools to present trustworthy data on diverse aspects such as statistics and facts on important aspects of the global Pediatric Neuroblastoma Treatment market.The approval of orphan drugs such as CLR 131 Phospholipid Drug Conjugate (PDC), developed by Cellectar Biosciences shall leverage the market during the forecast period (2020-2026), at a staggering CAGR of 9.2%.The report covers an analysis of the competitive landscape of the global Pediatric Neuroblastoma Treatment market together with a detailed study of the most important players working in this market.
The list of key players studied in this report includes:United Therapeutics CorporationAPEIRON Biologics AGBaxterBayer AGIn addition to this, the report sheds light on diverse strategies executed by market players to gain the leading position in the market for Pediatric Neuroblastoma Treatment.
Reports that gauge the healthcare industry have been made available by Market Research Future which creates reports on several industry verticals that review the market growth and prospects.
The market is projected to reach a CAGR of 3.7 % in the course of the forecast period.Request Sample Copy:https://www.marketresearchfuture.com/sample_request/6555Increased detection of cases related to neuroblastoma is primarily due to better detection methods and genetic predisposition to the disease.
The neuroblastoma market is expected to gather traction primarily due to research being conducted to treat the disease as well as better detection and treatment methods.
The end user segmentation of the neuroblastoma market comprises of research centers, hospitals, ambulatory surgical centers, diagnostic centers, and others.
The Americas region is projected to govern the neuroblastoma market due to a complex healthcare sector and rising incidences of childhood cancer.
The market development in this region is accredited to the growing number of infant cancer cases and the presence of established healthcare infrastructure.
Global Neuroblastoma Research Report: Information by Diagnostics (MIBG Scan and Biopsy), by Treatment (Surgical), and by End User (Hospitals and Others)—Forecast till 2027Neuroblastoma cases have increased significantly due to a range of factors from genetic to environmental factors.
Reports that gauge the healthcare industry have been made available by Market Research Future which creates reports on several industry verticals that review the market growth and prospects.
The market is projected to reach a CAGR of 3.7 % in the course of the forecast period.Increased detection of cases related to neuroblastoma is primarily due to better detection methods and genetic predisposition to the disease.
The end user segmentation of the neuroblastoma market comprises of research centers, hospitals, ambulatory surgical centers, diagnostic centers, and others.
The Americas region is projected to govern the neuroblastoma market due to a complex healthcare sector and rising incidences of childhood cancer.
The market development in this region is accredited to the growing number of infant cancer cases and the presence of established healthcare infrastructure.
